Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
暂无分享,去创建一个
C. O'connor | J. McMurray | J. Lewsey | J. Cleland | M. Metra | H. Krum | G. Jondeau | D. V. van Veldhuisen | M. Rainisio | I. Kobrin | G. Cotter | G. Torre-Amione | J. Parker | R. Bourge | J. Teerlink | A. Frey
[1] K. Swedberg,et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.
[2] A. Mebazaa,et al. The challenge of acute decompensated heart failure , 2006, Heart Failure Reviews.
[3] J. Cohn,et al. The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). , 2006, Journal of cardiac failure.
[4] N. Freemantle,et al. Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE , 2006, European journal of heart failure.
[5] J. Cleland,et al. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study , 2005, Heart.
[6] Luigi Tavazzi,et al. Acute Heart Failure Syndromes: Current State and Framework for Future Research , 2005, Circulation.
[7] William T. Abraham,et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness , 2005 .
[8] M. Nieminen,et al. Definition and epidemiology of acute heart failure syndromes. , 2005, The American journal of cardiology.
[9] C. O'connor,et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). , 2005, American heart journal.
[10] K. Aaronson,et al. Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials , 2005 .
[11] K. Aaronson,et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. , 2005, JAMA.
[12] Monica R. Shah,et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness The ESCAPE Trial , 2005 .
[13] K. Aaronson,et al. Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.
[14] D. DeMets,et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. , 2005, Journal of cardiac failure.
[15] K. Dickstein,et al. [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[16] D. Commenges,et al. Plasma endothelin in chronic heart failure. , 2005 .
[17] J. Ketelslegers,et al. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. , 2004, Journal of cardiac failure.
[18] C. Richter,et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure , 2004, European journal of heart failure.
[19] J. McMurray,et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.
[20] J. Teerlink,et al. A rational approach for the treatment of acute heart failure: current strategies and future options , 2004, Current opinion in cardiology.
[21] B. Lewis,et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. , 2003, Journal of the American College of Cardiology.
[22] V. Hasselblad,et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). , 2003, Journal of the American College of Cardiology.
[23] R. Zimlichman,,et al. Heart failure/transplant: abstractRITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema. A prospective, multicenter, double-blind, placebo-controlled study☆ , 2003 .
[24] J. Teerlink. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. , 2003, American heart journal.
[25] M. Nieminen,et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). , 2002, European heart journal.
[26] J. Cleland,et al. Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT‐2, MIRACLE‐ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL , 2002, European journal of heart failure.
[27] James B. Young. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .
[28] R. Califf,et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.
[29] A. Louis,et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ‐2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001 , 2001, European journal of heart failure.
[30] D. Mann,et al. Hemodynamic Effects of Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist, in Patients With Class III to IV Congestive Heart Failure , 2001, Circulation.
[31] S. Gottlieb,et al. Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure , 2000, Circulation.
[32] T. LeJemtel,et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. , 2000, The New England journal of medicine.
[33] Orton,et al. INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE , 2000 .
[34] J. McMurray,et al. A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. , 1999, Chest.
[35] J. McMurray,et al. Plasma Endothelin in Chronic Heart Failure , 1992, Circulation.